Common errors in the management of the seriously ill patient with inflammatory bowel disease;Errores frecuentes en el manejo del paciente grave con enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 30, Issue 5, 2007, Pages 294-314

  Gisbert, Javier P ^a,c   Gomollón, Fernando ^b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c Playa de Mojacar   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDIARRHEAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; STEROID;

ABDOMINAL ABSCESS; ABDOMINAL RADIOGRAPHY; ABDOMINAL SURGERY; CLINICAL FEATURE; COLON DILATATION; COLONOSCOPY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DYSPNEA; ENTERITIS; GASTROINTESTINAL ENDOSCOPY; HUMAN; HYPERTENSION; INTESTINE STENOSIS; MEDICAL ERROR; MEDICAL INFORMATION; NAUSEA; PYODERMA GANGRENOSUM; REVIEW; RISK FACTOR; THROMBOEMBOLISM; ULCERATIVE COLITIS;

EID: 34250325923     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13101982     Document Type: Article

References (299)

1. McKeown T. Los orígenes de las enfermedades humanas. Madrid: Triacastela; 2006.
2. Ilich I. Némesis médica. México: Joaquín Mortiz; 1978.
3. a ed. Barcelona: Ariel; 2005.
4. Farmer P. Infections and inequalities. Berkeley: University of California Press; 1999.
5. Reason J. Human error: models and management. BMJ. 2000; 320:768-70.
6. Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington, DC: National Academies Press; 1999.
7. Reason J. Beyond the organisational accident: the need for «error wisdom» on the frontline. Qual Saf Health Care. 2004; 13 Suppl 2:28-33.
8. Brennan TA, Gawande A, Thomas E, Studdert D. Accidental deaths, saved lives, and improved quality. N Engl J Med. 2005;353:1405-9.
9. Studdert DM, Mello MM, Gawande AA, Gandhi TK, Kachalia A, Yoon C, et al. Claims, errors, and compensation payments in medical malpractice litigation. N Engl J Med. 2006; 354:2024-33.
10. Leape LL, Berwick DM. Safe health care: are we up to it? Bmj. 2000;320:725-6.
11. Helmreich RL. On error management: lessons from aviation. Bmj. 2000;320:781-5.
12. Reason J. Safety in the operating theatre (II): human error and organisational failure. Qual Saf Health Care. 2005;14:56-60.
13. Daperno M, Sostegni R, Rocca R, Rigazio C, Scaglione N, Castellino F, et al. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther. 2002;16 Suppl 4:7-12.
14. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955;241:1041-8.
15. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;170 Suppl:2-6 [discussion 16-9].
16. Leiper K, London IJ, Rhodes JM. Management of the first presentation of severe acute colitis. Baillieres Clin Gastroenterol. 1997;11:129-51.
17. Tedesco FJ, Moore S. Infectious diseases mimicking inflammatory bowel disease. Am Surg. 1982;48:243-9.
18. Farmer RG. Infectious causes of diarrhea in the differential diagnosis of inflammatory bowel disease. Med Clin North Am. 1990;74:29-38.
19. Domenech E, García-Planella E, Mañosa M. Infecciones en la enfermedad inflamatoria intestinal. Enfermedad Inflamatoria Intestinal al Día. 2006;5:8-14.
20. Rolny P, Jarnerot G, Mollby R. Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand J Gastroenterol. 1983;18:61-4.
21. Greenfield C, Aguilar Ramírez JR, Pounder RE, Williams T, Danvers M, Marper SR, et al. Clostridium difficile and inflammatory bowel disease. Gut. 1983;24:713-7.
22. Weber P, Koch M, Heizmann WR, Scheurlen M, Jenss H, Hartmann F. Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol. 1992;14:302-8.
23. Kochhar R, Ayyagari A, Goenka MK, Dhali GK, Aggarwal R, Mehta SK. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol. 1993;16:26-30.
24. Stallmach A, Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm Bowel Dis. 2002;8:213-8.
25. Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775-8.
26. Banerjee S, Peppercorn MA. Inflammatory bowel disease. Medical therapy of specific clinical presentations. Gastroenterol Clin North Am. 2002;31:185-202.
27. Cheung O, Regueiro MD. Inflammatory bowel disease emergencies. Gastroenterol Clin North Am. 2003;32:1269-88.
28. Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33: 319-34.
29. Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterol Clin North Am. 2004;33:235-50.
30. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:1-16.
31. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99: 1371-85.
32. Collins P, Rhodes J. Ulcerative colitis: diagnosis and management. Bmj. 2006;333:340-3.
33. Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol. 2004;38:772-5.
34. Navarro M, Bernal I, Sánchez-Delgado J, Doménech E, García-Planella E, Mañosa M, et al. Estudio prospectivo sobre la incidencia de infección gastrointestinal por enteropatógenos en pacientes con enfermdad inflamatoria intestinal en brote de actividad. Gastroenterol Hepatol. 2006;28:168.
35. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-9.
36. Doménech E, Esteve M, Gomollon F, Hinojosa J, Panes J, Obrador A, et al. GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease. Gastroenterol Hepatol. 2005;28:126-34.
37. Travis SP. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther. 2004;20 Suppl 4:88-92.
38. Bolton RP, Sherriff RJ, Read AE. Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet. 1980;1:383-4.
39. Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology. 1981;80:693-6.
40. Meyers S, Mayer L, Bottone E, Desmond E, Janowitz HD. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology. 1981;80: 697-70.
41. Hyams JS, McLaughlin JC. Lack of relationship between Clostridium difficile toxin and inflammatory bowel disease in children. J Clin Gastroenterol. 1985;7:387-90.
42. Gryboski JD. Clostridium difficile in inflammatory bowel disease relapse. J Pediatr Gastroenterol Nutr. 1991;13:39-41.
43. Farrell RJ, LaMont JT. Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis. Curr Top Microbiol Immunol. 2000;250:109-25.
44. Keighley MR, Youngs D, Johnson M, Allan RN, Burdon DW. Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease. Gut. 1982;23:410-4.
45. LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet. 1980;1:381-3.
46. Trnka YM, Lamont JT. Clostridium difficile colitis. Adv Intern Med. 1984;29:85-107.
47. a ed. Gassull MA, Gomollón F, Obrador A, Hinojosa J, editores. Madrid: Ergon; 2002. p. 303-13.
48. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55 Suppl 1:1-15.
49. Scotiniotis I, Rubesin SE, Ginsberg GG. Imaging modalities in inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:391-421.
50. Almer S, Bodemar G, Franzen L, Lindstrom E, Noren B, Strom M. Plain X-ray films and air enema films reflect severe mucosal inflammation in acute ulcerative colitis. Digestión. 1995;56:528-33.
51. Caprilli R, Vernia P, Latella G, Torsoli A. Early recognition of toxic megacolon. J Clin Gastroenterol. 1987;9:160-4.
52. Chew CN, Nolan DJ, Jewell DP. Small bowel gas in severe ulcerative colitis. Gut. 1991;32:1535-7.
53. Yeung KW, Chang MS, Hsiao CP, Huang JF. CT evaluation of gastrointestinal tract perforation. Clin Imaging. 2004;28: 329-33.
54. Marshak RH. More on colonoscopy in inflammatory bowel disease [letter]. Gastroenterology. 1976;70:147.
55. Present DH. Toxic megacolon. Med Clin North Am. 1993; 77:1129-48.
56. The role of colonoscopy in the management of patients with inflammatory bowel disease. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc. 1998;48:689-90.
57. González Lara V, Pérez Calle JL, Marín Jiménez I. Actitud ante un megacolon tóxico. Rev Esp Enferm Dig. 2003;95: 415-21.
58. Koudahl G, Kristensen M. Toxic megacolon in ulcerative colitis. Scand J Gastroenterol. 1975;10:417-21.
59. Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol. 2003;98:2363-71.
60. Rizzello F, Gionchetti P, Venturi A, Campieri M. Review article: medical treatment of severe ulcerative colitis. Aliment Pharmacol Ther. 2003;17 Suppl 2:7-10.
61. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005;3:11-24.
62. Alemayehu G, Jarnerot G. Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol. 1991;86: 187-90.
63. Froehlich F, Larequi-Lauber T, Gonvers JJ, Dubois RW, Burnand B, Vader JP. Appropriateness of colonoscopy: inflammatory bowel disease. Endoscopy. 1999;31:647-53.
64. Lee SD, Cohen RD. Endoscopy in inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:119-32.
65. Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006;63:558-65.
66. Gomollon F. Assessment of intestinal inflammatory disease activity using gammagraphy with 99mTc-HMPAO-labelled leukocytes. Rev Esp Enferm Dig. 1997;89:653-6.
67. Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg. 2002;184:45-51.
68. Yamaguchi A, Matsui T, Sakurai T, Ueki T, Nakabayashi S, Yao T, et al. The clinical characteristics and outcome of intra-abdominal abscess in Crohn's disease. J Gastroenterol. 2004; 39:441-8.
69. Keighley MR, Eastwood D, Ambrose NS, Allan RN, Burdon DW. Incidence and microbiology of abdominal and pelvic abscess in Crohn's disease. Gastroenterology. 1982;83:1271-5.
70. Lambiase RE, Cronan JJ, Dorfman GS, Paolella LP, Haas RA. Percutaneous drainage of abscesses in patients with Crohn disease. AJR Am J Roentgenol. 1988;150:1043-5.
71. Doemeny JM, Burke DR, Meranze SG. Percutaneous drainage of abscesses in patients with Crohn's disease. Gastrointest Radiol. 1988;13:237-41.
72. Cybulsky IJ, Tam P. Intra-abdominal abscesses in Crohn's disease. Am Surg. 1990;56:678-82.
73. Ribeiro MB, Greenstein AJ, Yamazaki Y, Aufses AH Jr. Intra-abdominal abscess in regional enteritis. Ann Surg. 1991; 213:32-6.
74. Maeda K, Okada M, Yao T, Sakurai T, Iida M, Fuchigami T, et al. Intestinal and extraintestinal complications of Crohn's disease: predictors and cumulative probability of complications. J Gastroenterol. 1994;29:577-82.
75. Jawhari A, Kamm MA, Ong C, Forbes A, Bartram CI, Hawley PR. Intra-abdominal and pelvic abscess in Crohn's disease: results of noninvasive and surgical management. Br J Surg. 1998;85:367-71.
76. Parkes M, Jewell DP. Review article: the management of severe Crohn's disease. Aliment Pharmacol Ther. 2001;15:563-73.
77. Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M. Review article: the management of refractory Crohn's disease. Aliment Pharmacol Ther. 2002;16 Suppl 4:40-7.
78. Shanahan F. Crohn's disease. Lancet. 2002;359:62-9.
79. Scribano M, Prantera C. Review article: medical treatment of moderate to severe Crohn's disease. Aliment Pharmacol Ther. 2003;17 Suppl 2:23-30.
80. Lee H, Kim YH, Kim YH, Chang DK, Son HJ, Rhee PL, et al. Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease. Dig Liver Dis. 2006;38:659-64.
81. García JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. J Clin Gastroenterol. 2001;32:409-12.
82. Michetti P, Mottet C, Juillerat P, Felley C, Vader JP, Burnand B, et al. Severe and steroid-resistant Crohn's disease. Digestion. 2005;71:19-25.
83. Mortensen NJ. Abscess and Crohn's disease. Early surgery or percutaneous drainage? A British view. Dig Liver Dis. 2006; 38:666-7.
84. Olak J, Christou NV, Stein LA, Casola G, Meakins JL. Operative vs percutaneous drainage of intra-abdominal abscesses. Comparison of morbidity and mortality. Arch Surg. 1986;121: 141-6.
85. Casola G, Van Sonnenberg E, Neff CC, Saba RM, Withers C, Emarine CW. Abscesses in Crohn disease: percutaneous drainage. Radiology. 1987;163:19-22.
86. Safrit HD, Mauro MA, Jaques PF. Percutaneous abscess drainage in Crohn's disease. AJR Am J Roentgenol. 1987;148: 859-62.
87. Ayuk P, Williams N, Scott NA, Nicholson DA, Irving MH. Management of intra-abdominal abscesses in Crohn's disease. Ann R Coll Surg Engl. 1996;78:5-10.
88. Sahai A, Belair M, Gianfelice D, Cote S, Gratton J, Lahaie R. Percutaneous drainage of intra-abdominal abscesses in Crohn's disease: short and long-term outcome. Am J Gastroenterol. 1997;92:275-8.
89. Gervais DA, Hahn PF, O'Neill MJ, Mueller PR. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. Radiology. 2002;222:645-51.
90. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55 Suppl 1:16-35.
91. Golfieri R, Cappelli A, Giampalma E, Rizzello F, Gionchetti P, Laureti S, et al. CT-guided percutaneous pelvic abscess drainage in Crohn's disease. Tech Coloproctol. 2006;10:99-105.
92. Nath SK, Pasricha PJ. Abscess in Crohn's disease. The knife may not be necessary (an American view). Dig Liver Dis. 2006;38:665-6.
93. Gutierrez A, Lee H, Sands BE. Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol. 2006;101:2283-9.
94. Brihier H, Nion-Larmurier I, Afchain P, Tiret E, Beaugerie L, Gendre JP, et al. Intestinal perforation in Crohn's disease. Factors predictive of surgical resection. Gastroenterol Clin Biol. 2005;29:1105-11.
95. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77: 847-69.
96. Felder JB, Adler DJ, Korelitz BI. The safety of corticosteroid therapy in Crohn's disease with an abdominal mass. Am J Gastroenterol. 1991;86:1450-5.
97. Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum. 2000;43:1141-5.
98. Mahadevan U, Loftus EV Jr, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002;8:311-6.
99. Heuschen UA, Hinz U, Allemeyer EH, Autschbach F, Stern J, Lucas M, et al. Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. Ann Surg. 2002;235:207-16.
100. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125:320-7.
101. Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease. Clin Gastroenterol Hepatol. 2005;3:1215-20.
102. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology. 1975;68:627-35.
103. Epidemiological and clinical features of Spanish patients with Crohn's disease. Spanish Epidemiological and Economic Study Group on Crohn's disease. Eur J Gastroenterol Hepatol. 1999;11:1121-7.
104. Gisbert JP, Gomollon F, Mate J, Figueroa JM, Alos R, Pajares JM. Treatment of stenosis due to Crohn's disease. Gastroenterol Hepatol. 2002;25:560-9.
105. Sachar DB. Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:205-9.
106. Sheth SG, LaMont JT. Toxic megacolon. Lancet. 1998;351: 509-13.
107. Jalan KN, Circus W, Cord WI. An experience with ulcerative colitis: toxic dilatation in 55 cases. Gastroenterology. 1969; 57:68-82.
108. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5-36.
109. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-53.
110. Hommes DW, Sterringa G, Van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004;10:245-50.
111. Criscuoli V, Rizzuto MR, Cottone M. Cytomegalovirus and inflammatory bowel disease: is there a link? World J Gastroenterol. 2006;12:4813-8.
112. Kaufman HS, Kahn AC, Iacobuzio-Donahue C, Talamini MA, Lillemoe KD, Hamilton SR. Cytomegaloviral enterocolitis: clinical associations and outcome. Dis Colon Rectum. 1999; 42:24-30.
113. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:2137-42.
114. Loftus EV Jr. Hunting for the owl's eye in acute severe colitis: the role of cytomegalovirus. Dig Liver Dis. 2004;36:803-5.
115. Vega R, Bertran X, Menacho M, Doménech E, Moreno de Vega V, Hombrados M, et al. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94:1053-6.
116. Alcalá MJ, Casellas F, Pallarés J, De Torres I, Malagelada JR. Infección por citomegalovirus en pacientes con colitis ulcerosa tratados con colectomía. Med Clin (Barc). 2000;114:201-4.
117. Cottone M, Pietrosi G, Martorana G, Casa A, Pecoraro G, Oliva L, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol. 2001;96:773-5.
118. Wada Y, Matsui T, Matake H, Sakurai T, Yamamoto J, Kikuchi Y, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46: S59-65.
119. Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol. 2004;28:365-73.
120. Takahashi Y, Tange T. Prevalence of cytomegalovirus infection in inflammatory bowel disease patients. Dis Colon Rectum. 2004;47:722-6.
121. Criscuoli V, Casa A, Orlando A, Pecoraro G, Oliva L, Traina M, et al. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis. 2004;36:818-20.
122. Hamlin PJ, Shah MN, Scott N, Wyatt JI, Howdle PD. Systemic cytomegalovirus infection complicating ulcerative colitis: a case report and review of the literature. Postgrad Med J. 2004;80:233-5.
123. Diepersloot RJ, Kroes AC, Visser W, Jiwa NM, Rothbarth PH. Acute ulcerative proctocolitis associated with primary cytomegalovirus infection. Arch Intern Med. 1990;150:1749-51.
124. Lortholary O, Perronne C, Leport J, Leport C, Vilde JL. Primary cytomegalovirus infection associated with the onset of ulcerative colitis. Eur J Clin Microbiol Infect Dis. 1993;12: 570-2.
125. Orvar K, Murray J, Carmen G, Conklin J. Cytomegalovirus infection associated with onset of inflammatory bowel disease. Dig Dis Sci. 1993;38:2307-10.
126. Loftus EV Jr, Alexander GL, Carpenter HA. Cytomegalovirus as an exacerbating factor in ulcerative colitis. J Clin Gastroenterol. 1994;19:306-9.
127. Pfau P, Kochman ML, Furth EE, Lichtenstein GR. Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient. Am J Gastroenterol. 2001;96:895-9.
128. Swarbrick ET, Kingham JG, Price HL, Blackshaw AJ, Griffiths PD, Darougar S, et al. Chlamydia, cytomegalovirus, and Yersinia in inflammatory bowel disease. Lancet. 1979;2:11-2.
129. Eyre-Brook IA, Dundas S. Incidence and clinical significance of colonic cytomegalovirus infection in idiopathic inflammatory bowel disease requiring colectomy. Gut. 1986;27:1419-25.
130. Cooper HS, Raffensperger EC, Jonas L, Fitts WT Jr. Cytomegalovirus inclusions in patients with ulcerative colitis and toxic dilation requiring colonic resection. Gastroenterology. 1977; 72:1253-6.
131. Wakefield AJ, Fox JD, Sawyerr AM, Taylor JE, Sweenie CH, Smith M, et al. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction. J Med Virol. 1992;38:183-90.
132. Nishimoto Y, Matsumoto T, Suekane H, Shimizu M, Mikami Y, Iida M. Cytomegalovirus infection in a patient with ulcerative colitis: colonoscopic findings. Gastrointest Endosc. 2001; 53:816-8.
133. Brytting M, Xu W, Wahren B, Sundqvist VA. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol. 1992;30:1937-41.
134. Schmidt CA, Oettle H, Peng R, Neuhaus P, Blumhardt G, Lohmann R, et al. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation. 1995;59:1133-8.
135. Méndez JC, Espy MJ, Smith TF, Wilson JA, Paya CV. Evaluation of PCR primers for early diagnosis of cytomegalovirus infection following liver transplantation. J Clin Microbiol. 1998; 36:526-30.
136. Tsitoura DC, Rothman PB. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J Clin Invest. 2004;113:619-27.
137. Nos P, Hinojosa J. Ciclosporina en el brote grave de colitis ulcerosa. Gastroenterol Hepatol. 2005;28:629-31.
138. a ed. 2002. p. 351-8.
139. O'Sullivan M, O'Morain C. Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2006;20:561-73.
140. Dickinson RJ, Ashton MG, Axon AT, Smith RC, Yeung CK, Hill GL. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology. 1980;79:1199-204.
141. McIntyre PB, Powell-Tuck J, Wood SR, Lennard-Jones JE, Lerebours E, Hecketsweiler P, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut. 1986;27:481-5.
142. González-Huix F, Fernández-Banares F, Esteve-Comas M, Abad-Lacruz A, Cabre E, Acero D, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol. 1993;88:227-32.
143. Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17: 307-20.
144. Gassull MA. Review article: the role of nutrition in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20 Suppl 4:79-83.
145. Roediger WE. The starved colon: diminished mucosal nutrition, diminished absorption, and colitis. Dis Colon Rectum. 1990;33:858-62.
146. Dennis C, Karlson KE. Surgical measures as supplements to the management of idiopathic ulcerative colitis; cancer, cirrhosis, and arthritis as frequent complications. Surgery. 1952; 32:892-912.
147. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Complications. Gut. 1964;5:1-22.
148. Graef V, Baggenstoss AH, Seaur WG. Venous thrombosis occurring in non-specific ulcerative colitis. Arch Intern Med. 1966;117:377-82.
149. loan WP Jr, Bargen JA, Gage RB. Life histories of patients with chronic ulcerative colitis: a review of 2,000 cases. Gastroenterology. 1968;54 Suppl:819-22.
150. Talbot RW, Heppell J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140-5.
151. Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34: 247-51.
152. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. Qjm. 1997;90:183-8.
153. Koutroubakis IE. Role of thrombotic vascular risk factors in inflammatory bowel disease. Dig Dis. 2000;18:161-7.
154. Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85: 430-4.
155. Quera R, Shanahan F. Thromboembolism: an important manifestation of inflammatory bowel disease. Am J Gastroenterol. 2004;99:1971-3.
156. Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99:97-101.
157. Miehsler W, Reinisch W, Valic E, Osterode W, Tillinger W, Feichtenschlager T, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53:542-8.
158. Twig G, Zandman-Goddard G, Szyper-Kravitz M, Shoenfeld Y. Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann NY Acad Sci. 2005;1051:166-73.
159. Srirajaskanthan R, Winter M, Muller AF. Venous thrombosis in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2005;17:697-700.
160. Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005;3:617-28.
161. Hudson M, Chitolie A, Hutton RA, Smith MS, Pounder RE, Wakefield AJ. Thrombotic vascular risk factors in inflammatory bowel disease. Gut. 1996;38:733-7.
162. Spina L, Saibeni S, Battaglioli T, Peyvandi F, De Franchis R, Vecchi M. Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol. 2005;100: 2036-41.
163. Novacek G, Miehsler W, Kapiotis S, Katzenschlager R, Speiser W, Vogelsang H. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94:685-90.
164. Wong T, Nightingale J, Winter M, Muller AF. Spontaneous venous thrombosis in inflammatory bowel disease: relevance of factor V Leiden and the prothrombin gene mutation. J Thromb Haemost. 2003;1:1326-8.
165. Yassinger S, Adelman R, Cantor D, Halsted CH, Bolt RJ. Association of inflammatory bowel disease and large vascular lesions. Gastroenterology. 1976;71:844-6.
166. Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:266-72.
167. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819-31.
168. Capron JP, Remond A, Lebrec D, Delamarre J, Dupas JL, Lorriaux A. Gastrointestinal bleeding due to chronic portal vein thrombosis in ulcerative colitis. Dig Dis Sci. 1979;24:232-5.
169. Novotny DA, Rubin RJ, Slezak FA, Porter JA. Arterial thromboembolic complications of inflammatory bowel disease. Report of three cases. Dis Colon Rectum. 1992;35:193-6.
170. Oldenburg B, Fijnheer R, Van der Griend R, Van Berge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol. 2000;95:2825-30.
171. Oldenburg B, Van Tuyl BA, Van der Griend R, Fijnheer R, Van Berge Henegouwen GP. Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. Dig Dis Sci. 2005;50:235-40.
172. Kaya S, Hatemi I, Hamzaoglu I, Uzunismail H. Massive haemorrhage induced by low molecular weight heparin in a patient with steroid refractory ulcerative colitis. Scand J Gastroenterol. 2004;39:613.
173. Buning C, Lochs H. Conventional therapy for Crohn's disease. World J Gastroenterol. 2006;12:4794-806.
174. a ed. Madrid: Ergon; 2002. p. 327-34.
175. Katz JA. Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am. 2004;33:171-89, vii.
176. Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC. Assessment of severity in colitis: a preliminary study. Gut. 1975;16: 579-84.
177. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet. 1978;2:1086-8.
178. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984; 86:249-66.
179. Oshitani N, Kitano A, Fukushima R, Okabe H, Kashima K, Nakamura S, et al. Predictive factors for the response of ulcerative colitis patients during the acute-phase treatment. Digestion. 1990;46:107-13.
180. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811-8.
181. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1992;102:1647-53.
182. Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol. 1993;88: 852-5.
183. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-2.
184. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994;331:842-5.
185. Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current, medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol. 1995;20:280-4.
186. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 1996;8:905-9.
187. Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, et al. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up. Inflamm Bowel Dis. 1998;4:177-81.
188. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-60.
189. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002;97:803-23.
190. Abu-Suboh Abadia M, Casellas F, Vilaseca J, Malagelada JR. Response of first attack of inflammatory bowel disease requiring hospital admission to steroid therapy. Rev Esp Enferm Dig. 2004;96:539-44; 544-7.
191. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319-30.
192. Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. BMJ. 1959;25:387-94.
193. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067-70.
194. Buckell NA, Lennard-Jones JE. How district hospitals see acute colitis. Lancet. 1979;1:1226-9.
195. Meyers S, Sachar DB, Goldberg JD, Janowitz HD. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology. 1983;85:351-7.
196. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985; 89:1005-13.
197. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-10.
198. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831-5.
199. Carbonnel F, Gargouri D, Lemann M, Beaugerie L, Cattan S, Cosnes J, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14:273-9.
200. Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol. 2004;19:1247-52.
201. Daperno M, Sostegni R, Scaglione N, Ercole E, Rigazio C, Rocca R, et al. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis. 2004;36:21-8.
202. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079-87.
203. Benazzato L, D'Inca R, Grigoletto F, Perissinotto E, Medici V, Angriman I, et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis. 2004;36:461-6.
204. Bernal I, Manosa M, Doménech E, García-Planella E, Navarro M, Lorenzo-Zuniga V, et al. Predictors of clinical response to systemic steroids in active ulcerative colitis. Dig Dis Sci. 2006;51:1434-8.
205. Gelbmann CM. Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease: do we have reliable markers? Inflamm Bowel Dis. 2000;6:123-31.
206. Travis SP. Predicting outcome in severe ulcerative colitis. Dig Liver Dis. 2004;36:448-9.
207. Meyers S, Lerer PK, Feuer EJ, Johnson JW, Janowitz HD. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol. 1987;9:50-4.
208. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. BMJ. 1962; 5302:441-3.
209. Sandborn WJ. Evidence-based treatment algorithm for mild to moderate Crohn's disease. Am J Gastroenterol. 2003;98:1S-5S.
210. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935-9.
211. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-87.
212. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990;12:40-1.
213. Shaffer JA, Williams SE, Turnberg LA, Houston JB, Rowland M. Absorption of prednisolone in patients with Crohn's disease. Gut. 1983;24:182-6.
214. Shepherd HA, Barr GD, Jewell DP. Use of an intravenous steroid regimen in the treatment of acute Crohn's disease. J Clin Gastroenterol. 1986;8:154-9.
215. a ed. Madrid: Ergon; 2002. p. 315-25.
216. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-29.
217. García-López S, Gomollon-García F, Pérez-Gisbert J. Cyclosporin in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol. 2005;28:607-14.
218. Travis S. Review article: saving the colon in severe colitis: the case for medical therapy. Aliment Pharmacol Ther. 2006;24 Suppl 3:68-73.
219. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986;27:1210-2.
220. Meyers S, Janowitz HD. Systemic corticosteroid therapy of ulcerative colitis. Gastroenterology. 1985;89:1189-91.
221. Gold DM, Levine JJ, Weinstein TA, Kessler B, Pettei MJ. Prolonged medical therapy for severe pediatric ulcerative colitis. Am J Gastroenterol. 1995;90:732-5.
222. Fedorak RN. Conservative approach to severe ulcerative colitis. Dig Liver Dis. 2004;36:4-6.
223. Sachar DB. Clinical and colonoscopic surveillance in ulcerative colitis: are we saving colons or saving lives? Gastroenterology. 1993;105:588-97.
224. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001;15:1699-708.
225. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005;22:1-16.
226. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91: 423-33.
227. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001;48:591-2.
228. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000: CD000545.
229. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am. 2004;33:209-34.
230. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731-43.
231. Sandborn WJ, Van OE, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology. 1995;109:1808-17.
232. Casson DH, Davies SE, Thomson MA, Lewis A, Walker-Smith JA, Murch SH. Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease. Aliment Pharmacol Ther. 1999;13:891-5.
233. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999;117:527-35.
234. Rasmussen HH, Fonager K, Sorensen HT, Pedersen L, Dahlerup JF, Steffensen FH. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Scand J Gastroenterol. 1999;34: 199-201.
235. Weersma RK, Peters FT, Oostenbrug LE, Van den Berg AP, Van Haastert M, Ploeg RJ, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther. 2004;20:843-50.
236. Levine RA, McGuire RF. Corticosteroid-induced pancreatitis: a case report demonstrating recurrence with rechallenge. Am J Gastroenterol. 1988;83:1161-4.
237. McArthur KE. Review article: drug-induced pancreatitis. Aliment Pharmacol Ther. 1996;10:23-38.
238. Keljo DJ, Sugerman KS. Pancreatitis in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1997;25: 108-12.
239. Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol. 2003;98:1305-8.
240. Munk EM, Pedersen L, Floyd A, Norgard B, Rasmussen HH, Sorensen HT. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. Am J Gastroenterol. 2004;99:884-8.
241. Gisbert JP, Gomollon F, Mate J, Pajares JM. Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterol Hepatol. 2002;25:401-15.
242. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology. 1986;91:982-6.
243. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology. 1991;101:39-46.
244. Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol. 2003;37:220-5.
245. De Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2004;16:207-12.
246. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23:429-48.
247. Cappell MS, Das KM. Rapid development of pancreatitis following reuse of 6-mercaptopurine. J Clin Gastroenterol. 1989;11:679-81.
248. González-Lama Y, Gisbert JP. Ciclosporina y otros inmunomoduladores. Gastroenterología y Hepatología Continuada. Madrid: Doyma, S.A.; 2006. p. 57-61.
249. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005;CD004277.
250. Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol. 1997;92:1424-8.
251. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025-31.
252. Fernández-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol. 1996;91:2498-9.
253. Doménech E, García-Planella E, Bernal I, Rosinach M, Cabre E, Fluvia L, et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2002;16:2061-5.
254. Doménech E, Gomollon F, Obrador A, Panes J, Gassull MA. Is oral ciclosporin necessary to switch from i.v. to thiopurines? Aliment Pharmacol Ther. 2006;23:555-6; author reply 556-7.
255. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-77.
256. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469-77.
257. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-7.
258. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-9.
259. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-24.
260. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-13.
261. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
262. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-30.
263. Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003;134: 565-72 [discussion 572-3].
264. Subramanian V, Pollok RC, Kang JY, Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg. 2006;93:793-9.
265. Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878-83.
266. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004;19: 749-54.
267. Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006; 23:1127-36.
268. Judge T, Lichtenstein GR. The NOD2 gene and Crohn's disease: another triumph for molecular genetics. Gastroenterology. 2002;122:826-8.
269. Juillerat P, Mottet C, Froehlich F, Felley C, Vader JP, Burnand B, et al. Extraintestinal manifestations of Crohn's disease. Digestión. 2005;71:31-6.
270. Kethu SR. Extraintestinal manifestations of inflammatory bowel diseases. J Clin Gastroenterol. 2006;40:467-75.
271. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81:580-5.
272. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. Bmj. 2006;333:181-4.
273. Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581-5.
274. Harris AJ, Regan P, Burge S. Early diagnosis of pyoderma gangrenosum is important to prevent disfigurement. Bmj. 1998;316:52-3.
275. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273-83.
276. Campbell S, Cripps S, Jewell DP. Therapy Insight: pyoderma gangrenosum-old disease, new management. Nat Clin Pract Gastroenterol Hepatol. 2005;2:587-94.
277. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006;55 Suppl 1:36-58.
278. Friedman S, Marion JF, Scherl E, Rubin PH, Present DH. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:1-7.
279. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930-3.
280. Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2002;37:1108-10.
281. Romero-Gómez M, Sánchez-Munoz D. Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol. 2002;14:907.
282. Grange F, Djilali-Bouzina F, Weiss AM, Polette A, Guillaume JC. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology. 2002;205:278-80.
283. Zaccagna A, Bertone A, Puiatti P, Picciotto F, Sprujevnik T, Santucci R, et al. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol. 2003;13:258-60.
284. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821-6.
285. López San Roman A, Bermejo F, Aldanondo I, Carrera E, Boixeda D, Muñoz Zato E. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. Rev Esp Enferm Dig. 2004;96:420-2; 422-4.
286. Kaur MR, Lewis HM. Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol. 2005;153:689-91.
287. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505-9.
288. Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther. 2005;22:907-16.
289. Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs. 2005;65:2179-208.
290. Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs. 2005;65:2253-86.
291. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease: seven years on. Aliment Pharmacol Ther. 2006;23:451-63.
292. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-610.
293. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10: 135-9.
294. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol. 1997;115:61-4.
295. Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol. 1994;118:601-11.
296. Fries W, Giofre MR, Catanoso M, Lo Gullo R. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol. 2002;97:499-500.
297. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-6.
298. Markowitz J, Hyams J, Mack D, Leleiko N, Evans J, Kugathasan S, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1124-9.
299. Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4:1118-23.